Rein Therapeutics’ LTI-03 advances in Phase II IPF study
LTI-03, an IPF drug candidate, is progressing through a Phase II trial that is enrolling ahead of schedule, with dual-action claims to inhibit fibrosis and preserve lung progenitor cells.
Story updates
06:19:19 PM UTC
SquawkNews
A novel IPF therapy, LTI-03, targets both lung scarring and regeneration by mimicking caveolin-1, showing strong anti-fibrotic effects and preservation of progenitor cells. Early clinical trials confirm safety and biomarker improvements, with a phase II trial underway and interim data expected soon…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.